IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
Executive Summary
There were four biopharma IPOs in October – Myovant, Ra, CRISPR and AzurRX – but only one was trading above its offering price by the end of the month, reflecting investor uncertainty about the industry.
You may also be interested in...
CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?
CRISPR Therapeutics and Vertex initiated the first human study of CRISPR gene-editing technology with an industry sponsor, following an investigator-sponsored study initiated in China two years ago. These are not the first gene-editing trials, but they're important milestones for the CRISPR field.
Biopharma IPOs Gain Momentum As Three More Launch In The US
UroGen, Biohaven and Ovid bring the year's US biopharma IPO count to 11 as returns remain in mostly positive territory. Ovid is one of only two newly public drug developers trading below its offering price.
Start-Up Quarterly Statistics, Q4 2016
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.